On April 10, 2022, Mr. John Nemelka informed the board of directors (the Board") of Sanuwave Health, Inc. of his resignation as a member of the Board, effective immediately. Mr. Nemelka's resignation was not the result of any disagreement with the Company. On April 10, 2022, Messrs. Jeffrey Blizard, Ian Miller and Jim Tyler were appointed to the Board, effective immediately. Messrs. Blizard, Miller and Tyler will each serve as a director with terms expiring at the next annual meeting and until a successor has been duly elected and qualified. The Board appointed (i) Mr. Blizard
as the Chairman of the Compensation Committee and as a member of each of the Audit Committee and Nominating and
Corporate Governance Committee, (ii) Mr. Ian Miller as the Chairman of the Audit Committee, effective upon filing
of the Form 10-K for fiscal year 2021 and as a member of the Nominating and Corporate Governance Committee, effective immediately.
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. The Company is a provider of Food and Drug Administration (FDA)-approved wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and others. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression (PACE) technology to converge at precise selected targets to produce an extremely short duration compression burst.
SANUWAVE HEALTH, INC. 
